Importantly, S100A8 treatment significantly increased activities of these enzymes in lungs with LLC cancers (SOD: 117.1 ± 22.3 to 209.2 ± 22.0 nmol/min/mg protein, p < 0.05; TXN reductase: 6.6 ± 1.9 to 19.3 ± 3.9 nmol/min/mg protein, p < 0.05) to control levels (Figures 4A, B). This evidence concerns the gene S100A8 and cancer.